Predicting biotech clinical trials & a new Alzheimer’s drug controversy

The latest episode of "The Readout LOUD" podcast dives into a heated debate surrounding a new Alzheimer's drug, questioning its efficacy and ethical implications. It also explores the emerging trend of prediction markets that aim to forecast clinical trial outcomes and FDA decisions. This controversy is significant because it highlights the challenges in drug development and regulatory approval processes, especially for high-stakes treatments like those for Alzheimer's. The discussion underscores the need for transparency and rigorous evaluation in medical research.